As end of the year is approaching, there are activities at payers organization to assure that Xtandi would be used post Zytiga (Going off patent Dec 2015), in both pre and post chemo space in mCRPC. No doubt that Xtandi is a great drug but as there are no data out there showing that sequence of Xtandi------->Zytiga is better than Zytiga------->Xtandi then by the fact that generic drug is cheaper, then Zytiga would be used first. In the absence of true clinical trial data this is a reasonable approach.
Medivation is combating this with buying/partnering with BioMarin regarding their PARP inhibitor in BCa. This is sending a signal that despite the hype there is not much hope for Xtandi in BCa. Also, based on past data as well other PARP inhibitors currently in the market and or development; i.e., AZ drug etc., such drugs may have better activities in Ovarian Ca and even if BioMarin drug shows some activities in BCa, it would be the 3rd or at best second in the market. As some analyst have mentioned, MDVN remains a one trick pony and all these maneuvers is there to make sure stocks remain high in order for Executive Team members to sell off their shares at the highest rather than thinking about patients as they claim. Just look at the SEC website and you will notice the shares sold by rxecutive team members. MDVN share should not be more than $33-38 per share and anything above that is just company and market fooling investors.
Medivation is combating this with buying/partnering with BioMarin regarding their PARP inhibitor in BCa. This is sending a signal that despite the hype there is not much hope for Xtandi in BCa. Also, based on past data as well other PARP inhibitors currently in the market and or development; i.e., AZ drug etc., such drugs may have better activities in Ovarian Ca and even if BioMarin drug shows some activities in BCa, it would be the 3rd or at best second in the market. As some analyst have mentioned, MDVN remains a one trick pony and all these maneuvers is there to make sure stocks remain high in order for Executive Team members to sell off their shares at the highest rather than thinking about patients as they claim. Just look at the SEC website and you will notice the shares sold by rxecutive team members. MDVN share should not be more than $33-38 per share and anything above that is just company and market fooling investors.